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Abstract
Background: It was still unclear whether the methodological reporting quality of randomized controlled trials
(RCTs) in major hepato-gastroenterology journals improved after the Consolidated Standards of Reporting Trials
(CONSORT) Statement was revised in 2001.
Methods: RCTs in five major hepato-gastroenterology journals published in 1998 or 2008 were retrieved from
MEDLINE using a high sensitivity search method and their reporting quality of methodological details were
evaluated based on the CONSORT Statement and Cochrane Handbook for Systematic Reviews of interventions.
Changes of the methodological reporting quality between 2008 and 1998 were calculated by risk ratios with 95%
confidence intervals.
Results: A total of 107 RCTs published in 2008 and 99 RCTs published in 1998 were found. Compared to those in
1998, the proportion of RCTs that reported sequence generation (RR, 5.70; 95%CI 3.11-10.42), allocation
concealment (RR, 4.08; 95%CI 2.25-7.39), sample size calculation (RR, 3.83; 95%CI 2.10-6.98), incomplete outecome
data addressed (RR, 1.81; 95%CI, 1.03-3.17), intention-to-treat analyses (RR, 3.04; 95%CI 1.72-5.39) increased in 2008.
Blinding and intent-to-treat analysis were reported better in multi-center trials than in single-center trials. The
reporting of allocation concealment and blinding were better in industry-sponsored trials than in public-funded
trials. Compared with historical studies, the methodological reporting quality improved with time.
Conclusion: Although the reporting of several important methodological aspects improved in 2008 compared
with those published in 1998, which may indicate the researchers had increased awareness of and compliance
with the revised CONSORT statement, some items were still reported badly. There is much room for future
improvement.
Background
In the field of evidence-based medicine, randomized
controlled trials (RCTs) with a logical design and correct
implementation are considered to provide the best evi-
dence for healthcare interventions [1]. In order to assess
RCTs accurately, readers need complete, clear, and
transparent information with regards to the design and
conduction of the trials. Inappropriate experimental
design and/or reporting usually lead to confusion in
data interpretation. For example, unclear or inadequate
allocation concealment is associated with an overestima-
tion of treatment effect [2-4]. Therefore, adequate
reporting of clinical trials, especially the methodological
characteristics, is crucial for readers to appraise their
validity.
In order to improve the quality of reporting in RCTs,
the Consolidated Standards of Reporting Trials (CON-
SORT) statement was developed. Since it was published
in 1996, it has been gradually accepted by many medical
journals and has been associated with improvement of
the quality of RCT reporting [5-8]. The statement was
subsequently revised in 2001 and updated in 2010. We
conducted this study in an attempt to evaluate the
reporting qualities of key methodological items in RCTs
from five major hepato-gastroenterology journals in
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and in 2008, 7 years after its revised version. We
assessed whether the methodological reporting quality
has improved over this10 year period, especially before
and after the publication of the revised version of the
CONSORT in 2001.
Methods
Information source
We used a highly sensitive search strategy based on the
Cochrane Handbook for Systematic Reviews of Interven-
tions (Version 5.0.2) [9] to retrieve relevant RCTs pub-
lished in the five highest impact factor journals of
gastroenterology and hepatology (American Journal of
Gastroenterology, Gastroenterology, Gut, Hepatology,
and the Journal of Hepatology) in 1998 or 2008 from
MEDLINE. In order to identify missing RCTs, these five
journals were also manually searched.
Inclusion criteria
Only RCTs were eligible in our analysis. The trial was
defined as a RCT if “random” was mentioned when par-
ticipants were assigned to interventions. The following
trial reports were excluded: reports published in a sum-
mary form or as reviews of randomized trials, reports
on randomized trials on animals or healthy volunteers,
and reports that did not describe the intervention out-
come of randomly allocated patients.
Data extraction
Two authors (JW & TS), who were blinded to each
other’s results, screened all titles and abstracts of possi-
bly relevant RCTs, and then selected RCTs in accor-
dance with the predetermined eligibility criteria; studies
were discarded that were not applicable by reviewing
the full texts. One author (JW) extracted data from all
articles, while another (TS) randomly selected 50 RCTs
(24% of the sample) and extracted data independently
using the same methods. Differences generated in data
extraction were resolved by discussion and the senior
reviewer (JF) was asked for help when disagreement
could not be resolved by discussion.
Standards of methodological reporting
Based on the Cochrane Handbook for Systematic
Reviews of Interventions and the CONSORT statement
[10], seven items that were deemed important to avoid
bias of the effect estimation were extracted for assess-
ment. The seven methodological items were as follows:
(1) random allocation sequence generation, classified as
adequate reporting (when methods used to generate
random sequence, randomization type, and restriction
details were all reported), partial reporting (only parts of
detials were reported), and no reporting; (2) allocation
concealment, classified as adequate reporting (when
mechanism used to implement random sequence, and
whether concealed sequence until interventions assigned
were both reported), partial reporting (only parts of
details were reported), and no reporting; (3) blinding,
classified as adequate reporting (people who were
blinded after assignment to interventions and how
blinding was conducted, description of the similarity of
interventions were all reported), partial reporting (only
parts of details were reported), and no reporting; (4)
sample size calculation, classified as adequate reporting
(description of the methods of determining sample size
and explanation of any interim analyses and stopping
guidelines), partial reporting (only parts of details were
reported), and no reporting; (5) incomplete outcome
data addressed, classified as adequate reporting (missing
outcome data was shown and whether the missing out-
come data had a clinically relevant impact on interven-
tion effect estimate), partial reporting (only parts of
details were reported), and no reporting; (6) intention to
treat analysis, classified as adequate reporting (how
many participants were included in each analysis and
whether the analysis was by original assigned groups),
partial reporting (only parts of details were reported),
and no reporting; (7) free of selective reporting, classi-
fied as adequate reporting(reporting all planned primary
and secondary end points), partial reporting (only parts
of details were reported), and no reporting.
Data analysis
Cohen’s kappa analysis [11] was performed to measure
the level of agreement between the reviewers on all
items of the data abstraction form. Agreement was
judged as poor (kappa < 0.2), fair (0.21< kappa < 0.4),
moderate (0.41< kappa < 0.6), substantial (0.61< kappa
< 0.8), or good (kappa > 0.8).
We reported categorical data as frequencies, percen-
tages, and 95% confidence interval (95%CI), using the
Wilson Scoring method. Differences of the reporting
quality of key methodological items in proportions in
1998 versus 2008 were tested using Chi-square analysis,
a n de x p r e s s e da sr i s kr a t i o( R R )w i t h9 5 % C I .P - v a l u e s
were two-tailed and those < 0.05 were considered statis-
tically significant. All of the statistical analysis was con-
ducted using SAS 9.2 software (SAS Institute Inc. USA).
Results
Search results
Flow diagram of the search strategy and review process
was detailed in Figure 1. Finally, a total of 206 RCTs
(107 in 2008 and 99 published in 1998) were included.
K a p p as c o r e so fd a t ae x t r a c t e di n d e p e n d e n t l yb yt h e
two authors (JW and TS) werea l lg r e a t e rt h a n0 . 8 0 ,
indicating good agreement.
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RCTs published in 2008 with a median of 167 partici-
pants and a median of 356 days follow-up period cov-
ered 26 diseases, while RCTs in 1998, with a median of
94 participants and a median of 178 days follow-up per-
iod, covered 24 diseases. In 1998, single-center trials
were more common than multi-center trials, but in
2008 more than 70% of trials were conducted in multi-
ple centers. Funding source information is important for
readers to assess therapeutic effects. The number funded
by industry increased in 2008. Characteristics of the
included trials were detailed in Table 1.
Reporting of methodological items
Referring only to the items reported adequately, there
was an increase in the proportion of trial reports that
included adequate details of sequence generation (RR,
2.44; 95%CI 1.09-5.42; 10% in 1998 vs. 22% in 2008),
sample size calculation (RR, 2.34; 95%CI 1.14-4.84; 13%
in 1998 vs. 28% in 2008), intention-to-treat analysis (RR,
1.94; 95%CI 1.1-3.45; 30% in 1998 vs. 46% in 2008)
between 1998 and 2008. Considering items reported
adequately or partly as they had been reported, RCTs in
2008 had better reporting of the methodological items
of sequence generation (RR, 5.70; 95%CI 3.11-10.42;
35% in 1998 vs. 76% in 2008), allocation concealment
(RR, 4.08; 95%CI 2.25-7.39; 25% in 1998 vs. 62% in
2008), sample size calculation (RR, 3.83; 95%CI 2.10-
6.98; 47% in 1998 vs. 78% in 2008), intention-to-treat
analyses (RR, 3.04; 95%CI 1.72-5.39; 42% in 1998 vs.
69% in 2008), incomplete outcome data addressed (RR,
1.81; 95%CI 1.03-3.17; 34% in 1998 vs. 49% in 2008)
than those published in 1998. However, no clear differ-
ence emerged in the reporting of blinding (RR, 1.25;
95%CI 0.72-2.16), free of selective reporting (RR, 1.48;
95%CI 0.86-2.57), and free of other bias (RR, 0.90; 95%
CI 0.50-1.61) between the two selected years (Table 2).
Methodological reporting quality in 2008 according to
different strata
We explored the association between the methodologi-
cal reporting quality and center and funding source. In
this section, we also took the items reported adequately
or partly as they had been reported. The results showed
that the methods of blinding and intention-to-treat ana-
lysis are related to the number of centers involved.
Multi-center trials had better reporting of these two
methodological items than single-center trials. As for
the effects of different funding, allocation concealment
and blinding were observed to be reported better in
industry-sponsored trials than in public-funded trials.
The reporting of other items were not associated with
center or funding source (Table 3).
Discussion
Accurate description of methodology is essential for
readers to assess the internal and external validity of
RCTs. In this study, reporting quality of key methodolo-
gical items of RCTs published in five major gastroenter-
ology and hepatology journals in 2008 or 1998 were
systematically assessed and compared. We identified an
improvement in the key items of sequence generation,
allocation concealment, sample size calculation,
intention-to-treat analyses, and addressing of incomplete
outcome data in 2008 compared with 1998. Neverthe-
less, the methodological reporting quality was still
unsatisfactory.
Although the method of sequence generation was
reported in more than twice as many articles published
in 2008 than in 1998, 24% of articles still had inadequate
information about this item. According to the latest
CONSORT statement [10], adequate description of ran-
dom allocation sequence generation should contain at
least three aspects: methods used to generate the ran-
dom sequence, randomization type, and restriction
details. Applying these criteria to assessment of these
articles, the results were even more unsatisfactory. In
2008, 12 years after the CONSORT statement was first
published, only 23 articles adequately described how the
random allocation sequence was generated. Sequence
concealment allocation is also crucial to avoid bias, but
this item was not reported well either. In 1998, only a
quarter of articles reported that generated allocation
schedules were implemented by allocation concealment.
Ten years later, only half of trials reported adopting
allocation concealment. Without adequate information,
readers cannot define the exact method used. At the
same time, without adequate information readers were
unclear whether the randomization process was free
Figure 1 Flow diagram of the search strategy and review
process.
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valid because trials with poor or unexplained conceal-
ment were more likely to yield larger estimates of treat-
ment effect [12]. Therefore, not only details of the
mechanism used to implement the random allocation
sequence are required, but also the steps taken to con-
ceal the sequence, and who generated the random allo-
cation sequence, enrolled and assigned participants are
required.
In 1998, blinding was the best reported item among
the seven key methodological items, but no significant
improvement was observed in the next 10 years. This
finding was in agreement with Amy’s conclusion that
CONSORT adoption had little effect on blinding of par-
ticipants [13]. According to the CONSORT statement,
people who were blinded after assignment to interven-
tions and how the blinding was conducted should be all
reported. However, many articles only described trials as
“double blinded” or “blinded”, without providing any
details. In trials without reporting of blinding details,
bias may occur either intentionally or unintentionally, so
their results are not fully reliable. For patient-reported
outcomes in particular, result surveyors should make
every effort to eliminate measurement bias. A meta-epi-
demiological study found that effect estimates were
exaggerated when blinding had not taken place in trials
with subjective outcomes effect estimate [14].
An adequate number of participants is essential for
the detection of clinically significant differences with a
high power. From the results of previous studies [15-18]
and our article, the reporting quality of this item is gra-
dually improving. The internal validity of RCTs is also
associated with study participation and continuation.
Omitting participants withdrawing from the trials easily
reintroduced imbalance and prevented readers from cal-
culating the attrition rates for different experimental
conditions, which led to an overestimate of treatment
effectiveness [19]. However, this methodological item
was seldom assessed in previous articles evaluating the
methodological reporting of RCTs about digestive dis-
ease. To our knowledge, our study and Kjaergard’s study
[16] are the only two studies evaluating the reporting
condition of this item. Kjaergard only examined RCTs
published in Hepatology and found that drop-outs and
Table 1 Characteristics of included RCTs
Administrative indicators Trials in 2008 Trials in 1998 RR [95%CI] p value
No. (%) No. (%)
Top five kinds of disease
chronic hepatitis C 19(18%) 15(15%) 1.21 [0.58, 2.53] P = 0.62
inflammatory bowel disease 17(16%) 11(11%) 1.51 [0.67, 3.41] P = 0.32
liver cirrhosis 11(10%) 12(12%) - -
chronic hepatitis B 12(11%) - - -
colorectal cancer 8(7%) - - -
peptic ulcer - 15(15%) - -
liver cancer - 5(5%) - -
Region
North America 36(34%) 30(30%) 1.17 [0.65, 2.10] P = 0.61
Europe 42(39%) 56(57%) 0.50 [0.28, 0.86] P = 0.01
Asia 19(18%) 8(8%) 2.46 [1.02, 5.90] P = 0.04
Australia 10(9%) 4(4%) 2.45 [0.74, 8.08] P = 0.14
Center
Single-center 31(29%) 51(52%) 0.38 [0.22, 0.68] P = 0.001
Multi-center 76(71%) 48(48%) 2.60 [1.47, 4.63] P = 0.001
Funding source
Industry 43(40%) 25(25%) 1.99 [1.10, 3.61] P = 0.02
Public 40(38%) 32 (32%) 1.25 [0.70, 2.22] P = 0.45
Public and industry 13(12%) 8(8%) 1.57 [0.62, 3.97] P = 0.34
Not specified 5(5%) 33(33%) 0.10 [0.04, 0.26] P < 0.001
None 6(5%) 1(1%) 5.82 [0.69, 49.24] P = 0.11
Ethics committee approval 105(98%) 86(87%) 7.94 [1.74, 36.13] P = 0.007
Informed consent from patients 100(93%) 81(82%) 3.17 [1.26, 7.97] P = 0.01
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However, this item was reported only in 30% of RCTs
published in the five major gastroenterology and hepa-
tology journals in 1998 and 49% of RCTs published in
2008.
As for the effects of funds upon methodological
reporting quality, though there were different opinions
[20,21], industry-sponsored trials were reported to have
better reporting of methodology than non-industry
sponsored trials [15,22,23]. For example, both Brown A
[22] and Thomas O’s[ 2 3 ]s t u d yh a v ef o u n dt h a tt r i a l s
with industry funding had a higher methodology score
than those with public funding. Bai Y’s study [15] indi-
cated that those industry-sponsored trials had better
reporting of double blinding than public sponsored
trials. We also found that industry-sponsored trials were
significantly more likely to report the item of sequence
allocation concealment and blinding. Compared with
single-center trials, more participants were recruited by
the multi-center collaboration, which resulted in an
Table 2 Reporting quality of key methodological items
Items 2008(n = 107) 1998(n = 99) 2008 VS 1998
n(%) n(%) RR [95%CI] P value
Sequence generation
adequate reporting 23(22%) 10(10%) 2.44[1.09,5.42] < 0.05
partial reporting 58(54%) 25(25%) < 0.05
no reporting 26(24%) 64(75%) < 0.05
*adequate + partial reporting 81(76%) 35(35%) 5.70[3.11,10.42] < 0.05
Allocation concealment
adequate reporting 6(6%) 3(3%) 1.90[0.46,7.82] 0.89
partial reporting 56(52%) 22(22%) < 0.05
no reporting 45(42%) 74(75%) < 0.05
*adequate + partial reporting 62(58%) 25(25%) 4.08 [2.25, 7.39] < 0.05
Blinding
adequate reporting 24(22%) 22(22%) 1.01[0.52,1.95] 0.97
partial reporting 38(36%) 30(30%) 0.43
no reporting 45(42%) 47(47%) 0.43
*adequate + partial reporting 62(58%) 52(53%) 1.25 [0.72, 2.16] 0.43
Sample size calculation
adequate reporting 28(26%) 13(13%) 2.34[1.14,4.84] < 0.05
partial reporting 55(52%) 34(34%) < 0.05
no reporting 24(22%) 52(53%) < 0.05
*adequate + partial reporting 83(78%) 47(47%) 3.83 [2.10, 6.98] < 0.05
Incomplete outecome data addressed
adequate reporting 20(19%) 12(12%) 1.67[0.77,3.62] 0.2
partial reporting 32(30%) 22(22%) 0.21
no reporting 55(51%) 65(66%) < 0.05
*adequate + partial reporting 52(49%) 34(34%) 1.81[1.03,3.17] < 0.05
Intention-to-treat analysis
adequate reporting 49(46%) 30(30%) 1.94[1.10,3.45] < 0.05
partial reporting 25(23%) 12(12%) < 0.05
no reporting 33(31%) 57(58%) < 0.05
*adequate + partial reporting 74(69%) 42(42%) 3.04 [1.72, 5.39] < 0.05
Free of selective reporting
adequate reporting 34(32%) 20(20%) 1.84[0.97,3.48] 0.06
partial reporting 23(21%) 23(23%) 0.76
no reporting 50(47%) 56(57%) 0.16
*adequate + partial reporting 57(53%) 43(43%) 1.48[0.86,2.57] 0.16
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ference of methodological reporting quality between sin-
gle-center and multi-center trials and found only
blinding and “intention to treatment “ analysis were bet-
ter in multi-center trials though it was believed that
prospective studies, undertaken in collaboration (either
jointly or in parallel), could lead to the development of
treatments that are truly beneficial for patients with
these diseases [25].
In addition, we also compared this study with previous
studies [15-18] focusing on reporting methodological
quality of RCTs published in one or more gastroenterol-
ogy and hepatology journals, and found an improvement
of almost all methodological items after the revised ver-
sion of CONSORT in 2001(Shown in Table 4). Com-
p a r e dw i t ht h o s es t u d i e s[ 1 5 - 1 8 ] ,w eh a v ed o n eam o r e
comprehensive evaluation of the methodological
reporting, while some of the methodological items were
seldom assessed in previous studies, especially the items
related to incomplete outcome, ITT analysis and free of
selective reporting, which are also important for readers
to assess the internal validity of the RCTs.
In this study, we used a standardized and rigorous
evaluation instrument to assess the reporting of key
methodological items systematically, and the abstraction
processes were independently performed by two quali-
fied reviewers. However, there were still limitations in
this study. Firstly, we only included five major journals
and only assessed RCTs for two years due to time and
resource constraints, so the results could not represent
the methodological reporting quality of the entire range
of gastroenterology and hepatology journals. Secondly,
we did not compare the methodological reporting qual-
ity of these five journals before and after adopting the
Table 3 Methodological reporting in 2008 according to center and funding source
Sequence
generation
Allocation
concealment
Blinding Sample size
calculation
Incomplete
outecome
Intention-to-treat
analysis
Free of selective
reporting
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Center
Single-center 20(64%) 14(45%) 13(42%) 21(68%) 17(55%) 17(55%) 21(68%)
(n = 31)
Multi-center 61(80%) 48(63%) 49(64%) 62(82%) 35(46%) 57(75%) 36(47%)
(n = 76)
P value 0.08 0.09 0.03 0.12 0.41 0.04 0.06
Funding source
Industry 37(86%) 31(72%) 30(70%) 34(80%) 18(42%) 28(65%) 21(49%)
(n = 43)
Public 28(70%) 20(50%) 19(48%) 30(75%) 23(58%) 28(72%) 25(63%)
(n = 40)
P value 0.07 0.04 0.04 0.66 0.16 0.64 0.21
Table 4 Methodological reporting in major hepato-gastroenterology journals in different years
Gluud [17] Kjaergard [16] Current study Kjaergard [18] Bai [15] Current study
Study period 1985-1997 1981-1998 1998 1964-2000 2006 2008
Included journals the Journal of Hepatology Hepatology 5 * Gastroenterology 6* 5*
Number of RCTs 166 235 99 383 105 107
Sequence generation 47(28%) 121(51%) 35(35%) 161(42%) 85(81%) 81(76%)
Allocation concealment 22(13%) 80(34%) 25({25%) 149(39%) 64(61%) 62(58%)
Blinding 50(30%) 80(34%) 52(53%) 237(62%) 54(51%) 62(58%)
Sample size calculation 33(20%) 61(26%) 47(47%) - 79(75%) 83(78%)
Incomplete outcome - 165(70%) 34(34%) - - 52(49%)
Intention-to-treat analysis 95(57%) - 42(42%) - - 74(69%)
Free of selective reporting - - 43(43%) - - 57(53%)
*The current study included the five journals:American Journal of Gastroenterology, Gut, the Journal of Hepatology, Gastroenterology, Hepatology.
* The study of Bai included six journals:Gastroenterology, Hepatology, Gut, Journal of Hepatology, American Journal of Gastroenterology,
Clinical Gastroenterology and Hepatology
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the CONSORT statement was adopted by each journal,
but were unable to do so for three of them.
Conclusions
Our analysis, although not exhaustive, suggests a signifi-
cant improvement between 1998 and 2008 in the
reporting quality of key methodological items in the
major gastroenterology and hepatology journals, which
is most likely the result of compliance with the CON-
SORT Statement. However, we can see that there is still
ample room for improvement. Now the CONSORT
Statement 2010 edition has been published, we call on
authors and journal editors, especially those in Asia, to
support and implement it in order to enhance the qual-
ity of RCT reporting.
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